ReviewFrontiers in immunology2022
Notes on syphilis vaccine development.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Neurosyphilis-Induced Psychosis in Europe: A Systematic Review of Case Reports.Pathogens (Basel, Switzerland) · 2024Pooled it
- The Congenital Syphilis Surge: Clinician Lessons to Turn the Rising Tide.Advances in pediatrics · 2026Review
- Protective immunity induced by Tp0136 epitope vaccines with mRNA LNP or protein delivery.NPJ vaccines · 2025Article
- The changing epidemiology of syphilis: new strategies for new challenges in China.The Lancet regional health. Western Pacific · 2025Review
- Biologic drug development for treatment and prevention of sexually transmitted infections.Clinical microbiology reviews · 2025Review
- Antibodies directed against extracellular loops of FadL orthologs disrupt outer membrane integrity and neutralize infectivity ofFrontiers in immunology · 2025Article
- Syphilis vaccine development: Aligning vaccine design with manufacturing requirements.Human vaccines & immunotherapeutics · 2024Article
- Immunodominant extracellular loops of Treponema pallidum FadL outer membrane proteins elicit antibodies with opsonic and growth-inhibitory activities.PLoS pathogens · 2024Article
- Immunodominant extracellular loops ofbioRxiv : the preprint server for biology · 2024Article
- Comprehensive Overview ofCurrent protein & peptide science · 2024Review
- Insights into the protective immune response by immunization with full-length recombinant TprK protein: cellular and humoral responses.NPJ vaccines · 2023Article
- Longitudinal Variations in theMicrobiology spectrum · 2023Article
- Advancements in the development of nucleic acid vaccines for syphilis prevention and control.Human vaccines & immunotherapeutics · 2023Review
- Syphilis vaccine: challenges, controversies and opportunities.Frontiers in immunology · 2023Review
- Neurosyphilis: insights into its pathogenesis, susceptibility, diagnosis, treatment, and prevention.Frontiers in neurology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
The quest for a syphilis vaccine to provide protection from infection or disease began not long after the isolation of the first
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.